FR2868315B1 - Procede de preparation d'un compose d'inclusion soluble de substances actives dans une molecule hote avec l'aide d'un agent d'interaction par fluide supercritique - Google Patents

Procede de preparation d'un compose d'inclusion soluble de substances actives dans une molecule hote avec l'aide d'un agent d'interaction par fluide supercritique

Info

Publication number
FR2868315B1
FR2868315B1 FR0403450A FR0403450A FR2868315B1 FR 2868315 B1 FR2868315 B1 FR 2868315B1 FR 0403450 A FR0403450 A FR 0403450A FR 0403450 A FR0403450 A FR 0403450A FR 2868315 B1 FR2868315 B1 FR 2868315B1
Authority
FR
France
Prior art keywords
preparing
active substances
supercritical fluid
inclusion compound
host molecule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0403450A
Other languages
English (en)
Other versions
FR2868315A1 (fr
Inventor
Bernard Freiss
Florence Marciacq
Hubert Lochard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pierre Fabre Medicament SA
Original Assignee
Pierre Fabre Medicament SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR0403450A priority Critical patent/FR2868315B1/fr
Application filed by Pierre Fabre Medicament SA filed Critical Pierre Fabre Medicament SA
Priority to PCT/FR2005/000739 priority patent/WO2005097201A2/fr
Priority to ES10182089T priority patent/ES2424235T3/es
Priority to PT05744579T priority patent/PT1729813E/pt
Priority to JP2007505584A priority patent/JP5091661B2/ja
Priority to AT05744579T priority patent/ATE504316T1/de
Priority to EP10182089.2A priority patent/EP2260871B1/fr
Priority to EP05744579A priority patent/EP1729813B1/fr
Priority to CA2563101A priority patent/CA2563101C/fr
Priority to PL10182089T priority patent/PL2260871T3/pl
Priority to DE602005027333T priority patent/DE602005027333D1/de
Priority to PL05744579T priority patent/PL1729813T3/pl
Priority to US10/594,740 priority patent/US8461133B2/en
Priority to PT101820892T priority patent/PT2260871E/pt
Priority to SI200531739T priority patent/SI2260871T1/sl
Priority to DK10182089.2T priority patent/DK2260871T3/da
Priority to RU2006138488/15A priority patent/RU2382654C2/ru
Priority to ES05744579T priority patent/ES2364274T3/es
Priority to BRPI0509482A priority patent/BRPI0509482B1/pt
Priority to ARP050101306A priority patent/AR049488A1/es
Publication of FR2868315A1 publication Critical patent/FR2868315A1/fr
Publication of FR2868315B1 publication Critical patent/FR2868315B1/fr
Application granted granted Critical
Priority to US13/873,959 priority patent/US9243076B2/en
Priority to CY20131100671T priority patent/CY1114198T1/el
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
FR0403450A 2004-04-01 2004-04-01 Procede de preparation d'un compose d'inclusion soluble de substances actives dans une molecule hote avec l'aide d'un agent d'interaction par fluide supercritique Expired - Fee Related FR2868315B1 (fr)

Priority Applications (22)

Application Number Priority Date Filing Date Title
FR0403450A FR2868315B1 (fr) 2004-04-01 2004-04-01 Procede de preparation d'un compose d'inclusion soluble de substances actives dans une molecule hote avec l'aide d'un agent d'interaction par fluide supercritique
SI200531739T SI2260871T1 (sl) 2004-04-01 2005-03-29 Kompleksi sestavin, ki vključujejo piroksikam, ciklodekstrin in arginin
ES10182089T ES2424235T3 (es) 2004-04-01 2005-03-29 Complejos de inclusiones que comprenden piroxicam, una ciclodextrina y arginina
DK10182089.2T DK2260871T3 (da) 2004-04-01 2005-03-29 Inklusionskomplekser omfattende piroxicam, en cyklodextrin og arginin
AT05744579T ATE504316T1 (de) 2004-04-01 2005-03-29 Einschlusskomplexe enthaltend piroxicam, ein cyklodextrin und arginin
EP10182089.2A EP2260871B1 (fr) 2004-04-01 2005-03-29 Complexes d'inclusions comprenant du piroxicam, une cyclodextrine et l'arginine
EP05744579A EP1729813B1 (fr) 2004-04-01 2005-03-29 Complexes d'inclusions comprenant du piroxicam, une cyclodextrine et l'arginine
CA2563101A CA2563101C (fr) 2004-04-01 2005-03-29 Complexes d'inclusions obtenus en utilisant un procede avec co2 supercritique et un agent d'interaction avec le complexe
PL10182089T PL2260871T3 (pl) 2004-04-01 2005-03-29 Kompleksy inkluzyjne zawierające piroksykam, cyklodekstrynę i argininę
DE602005027333T DE602005027333D1 (de) 2004-04-01 2005-03-29 Einschlusskomplexe enthaltend piroxicam, ein cyklodextrin und arginin
PL05744579T PL1729813T3 (pl) 2004-04-01 2005-03-29 Kompleksy inkluzyjne zawierające piroksykam, cyklodekstrynę i argininę
US10/594,740 US8461133B2 (en) 2004-04-01 2005-03-29 Inclusion complexes containing an active substance, a cyclodextrin and an agent for interaction
PCT/FR2005/000739 WO2005097201A2 (fr) 2004-04-01 2005-03-29 Complexes d’inclusions comprenant du piroxicam, une cyclodextrine et l’arginine
PT05744579T PT1729813E (pt) 2004-04-01 2005-03-29 Complexos de inclusão obtidos utilizando um processo com co2 supercrítico e um agente de interacção com o complexo
JP2007505584A JP5091661B2 (ja) 2004-04-01 2005-03-29 超臨界ｃｏ２と錯体相互作用剤を用いる方法によって得られる包接錯体
RU2006138488/15A RU2382654C2 (ru) 2004-04-01 2005-03-29 Комплексы включения, полученные способом с использованием co2 в сверхкритическом состоянии и агента взаимодействия с комплексом
ES05744579T ES2364274T3 (es) 2004-04-01 2005-03-29 Complejos de inclusiones que comprenden piroxicam, una ciclodextrina y arginina.
BRPI0509482A BRPI0509482B1 (pt) 2004-04-01 2005-03-29 complexo de inclusão, processo de preparação de um complexo de inclusão, e composição farmacêutica
PT101820892T PT2260871E (pt) 2004-04-01 2005-03-29 Complexos de inclusão obtidos utilizando um processo com co2 supercrítico e um agente para interação com o complexo
ARP050101306A AR049488A1 (es) 2004-04-01 2005-04-01 Complejos de inclusiones obtenidos al utilizar un procedimiento con co2 supercritico y un agente de interaccion con el complejo
US13/873,959 US9243076B2 (en) 2004-04-01 2013-04-30 Inclusion complexes containing piroxicam, a cyclodextrin and arginine
CY20131100671T CY1114198T1 (el) 2004-04-01 2013-08-07 Συμπλοκα εγκλεισμου που περιεχουν πιροξικαμη, μια κυκλοδεξτρινη και αργινινη

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0403450A FR2868315B1 (fr) 2004-04-01 2004-04-01 Procede de preparation d'un compose d'inclusion soluble de substances actives dans une molecule hote avec l'aide d'un agent d'interaction par fluide supercritique

Publications (2)

Publication Number Publication Date
FR2868315A1 FR2868315A1 (fr) 2005-10-07
FR2868315B1 true FR2868315B1 (fr) 2006-07-14

Family

ID=34944522

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0403450A Expired - Fee Related FR2868315B1 (fr) 2004-04-01 2004-04-01 Procede de preparation d'un compose d'inclusion soluble de substances actives dans une molecule hote avec l'aide d'un agent d'interaction par fluide supercritique

Country Status (2)

Country Link
ES (1) ES2364274T3 (fr)
FR (1) FR2868315B1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2914187B1 (fr) * 2007-03-28 2011-01-21 Pf Medicament Complexes d'ibuprofene, de cyclodextrines et d'agents ternaires, et leurs utilisations en pharmaceutique.

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1241088B (it) * 1990-03-27 1993-12-29 Chiesi Farma Spa Procedimento per la preparazione di complessi piroxicam/ciclodestrina,prodotti ottenuti e loro composizioni farmaceutiche
FR2815540B1 (fr) * 2000-10-19 2005-06-10 Separex Sa Procede de fabrication de tres fines particules constituees d'un principe insere dans une molecule hote
FR2830760B1 (fr) * 2001-10-12 2004-06-04 Pf Medicament Procede de preparation d'un compose d'interaction de substances actives avec un support poreux par fluide supercritique
DE60219609T2 (de) * 2002-06-17 2008-01-03 Chiesi Farmaceutici S.P.A. Prozess für die Vorbereitung von Piroxicam: Beta-Cyclodextrin Einschlusskomplexe

Also Published As

Publication number Publication date
FR2868315A1 (fr) 2005-10-07
ES2364274T3 (es) 2011-08-30

Similar Documents

Publication Publication Date Title
FR20C1005I1 (fr) Solution de chlorure de sodium pour la reconstitution de medicaments
HRP20150119T1 (hr) N-supstituirani derivati glicina kao inhibitori hidroksilaze
GT200600496A (es) Sales, profarmacos y formulaciones de 1-[5-(4-amino-7-isopropil-7h-pirrolo[2,3-d]piirimidin-5-carbonil)-2-metoxi-feil]-3-(2,4-dicloro-fenil)-urea.
JP2008511597A5 (fr)
EE05378B1 (et) LahustuvaÁCTLA4ÁsulandmolekuliÁkasutamineÁravimkoostiseÁvalmistamiseks
FR2887335B1 (fr) Procede pour la determination d'une contamination pathogene dans un fluide contenant des plaquettes sanguines
FR2892644B1 (fr) Structure de garnissage pour colonne d'echange de fluides
PL1932522T3 (pl) Środek terapeutyczny do leczenia choroby wątroby zawierający jako składnik czynny pochodną 2-amino-1,3-propanodiolu
JP2008518976A5 (fr)
EP2550965A3 (fr) Dérivés de céramide pour le traitement de la polykystose rénale
FR2868315B1 (fr) Procede de preparation d'un compose d'inclusion soluble de substances actives dans une molecule hote avec l'aide d'un agent d'interaction par fluide supercritique
WO2007088129A3 (fr) composes pour imagerie diagnostique au moins bimodale
ZA200805703B (en) Preparation of pharmaceutical salts of 3-0-(3',3'-dimethyl-succinyl) betulinic acid
WO2004064771A3 (fr) Derives de nsaid a disubstitution geminale servant d'agents reducteurs de abeta 42
FR2879427B1 (fr) Outil de travail rotatif et appareil electromenager de preparation culinaire prevus pour la realisation de preparations liquides
FR2904556B1 (fr) Utilisation d'un extrait de pois en tant qu'agent actif pour augmenter la synthese de melanine dans les melanocytes
HK1086819A1 (en) 2-(butyl-1-sulfonylamino)-n-(1(r)-(6-methoxy-pyridin-3-yl)-propyl)-benzamid, the use thereof in the form of drug an pharmaceutical preparations containing said compound
FR2869615B1 (fr) Derives de l'acide butanoique, procedes pour leur preparation, compositions pharmaceutiques les contenant et leurs applications therapeutiques
FR2918566B1 (fr) Composition pharmaceutique stable d'un sel hydrosoluble de vinflunine.
FR2886747B1 (fr) Procede pour la fabrication par stratoconception d'une piece traversee par des canaux de transfert de fluides prevus dans les interstrates
FR2883754B1 (fr) Utilisation de composes inducteurs de la synthese des proteines sirt dans ou pour la preparation d'une composition cosmetique ou pharmaceutique
FR2889691B1 (fr) Dispositif de distribution d'un produit fluide sous forme de goutte
FR2891287B1 (fr) Machine de realisation d'une paroi continue dans le sol
FR2925335B1 (fr) Compositions orales liquides de florfenicol diluables dans l'eau de boisson
FR2894144B1 (fr) Utilisation du dipeptide tyrosine-arginine dans une composition cosmetique ou pour la preparation d'un medicament

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 13

PLFP Fee payment

Year of fee payment: 14

PLFP Fee payment

Year of fee payment: 15

ST Notification of lapse

Effective date: 20191206